基于关联规则的中医治疗肺纤维化组方规律研究
Analysis on Compatibility of Prescription Regularity for Pulmonary Fibrosis Based on Relevance Rule
-
摘要: 目的 探讨肺纤维化中医临床方药配伍规律。方法 检索2005-2014年中国知网(CNKI)、中国生物医学文献数据库(CBM)和中国中医文献检索系统数据库(TCM)有关中医药治疗PF的文献。采用频数分析、基于遗传算法的双向强关联规则对纳入182首方药进行分析。结果 使用频数最高的是黄芪等补气药,其次是丹参等活血药。关联规则分析结果显示益气药多与活血药、健脾药配伍;药味以甘补为主,兼有苦辛;归经以肺、肝经为多。结论 益气活血是中医药治疗PF的基本配伍组合,另外健脾益肺的配伍亦较多。说明益气活血,健脾益肺是治疗PF的基本治疗大法。Abstract: OBJECTIVE To explore the compatibility of prescription for pulmonary fibrosis. METHODS The literature on the treatment of pulmonary fibrosis (PF) in China National Knowledge Internet (CNKI), the Chinese Biomedical Literature (CBM) and the Chinese Traditional Medicine Document Retrieval System Database (TCM) from 2005 to 2014 was searched. The "frequency analysis" and "genetic algorithm-oriented analysis of strong biderecrional relevance rule" were used to analysis 182 prescriptions. RESULTS The highest frequency of use is Radix Astragali and other tonifying qi medicinal, followed by Radix et Rhizoma Salviae Miltiorrhizae and other activating blood medicinal. The results of the relevance rule analysis showed that tonifying qi medicinal was more compatible with blood-activating and fortify the spleen medicinal. The flavor of medicine was dominated by sweetness, accompanied with bitterness and pungency, which is high frequency to lung and liver meridian. CONCLUSION The tonifying qi and activating blood medicinal are proved to be the fundamental compatibility for PF therapy in Chinese medicine, there are also more combinations of fortify the spleen and supplement the lung. It means that tonify qi and activate blood, fortify the spleen and supplement the lung are the basic treatment for PF.
-
[1] 王吉耀.内科学[M].北京:人民卫生出版社,2010:130142.〖ZK)〗 [2] RAGUH G, COLLARD HR, EGAN JJ,et al. An official STS/ERS/JRS/ALAT Statement: idiopathic; pulmonary fibrosis: evidenc; ebased guidelines for diagnosis and management[J]. Am J Respire Crit Care Med, 2011, 1839(6): 788824.〖ZK)〗 [3] SONG JW, HONG SB, LIM CM et al. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome[J]. Eur Respir, 2011,37(2):356363.〖ZK)〗 [4] 蒋永光,李认书,黎勇.试论中医方剂信息的数据化[J].中国中医药信息杂志,2001,8(12):8081〖ZK)〗 [5] 中华医学会呼吸病学分会.特发性肺(间质)纤维化诊断和治疗指南(草案)[J].中华结核和呼吸杂志,2002,25(7):387389.〖ZK)〗 [6] 钟赣生.中药学[M].北京:中国中医药出版社,2012.〖ZK)〗 [7] 中华人民共和国药典委员会.中国药典[M].北京:中国医药科技出版社,2010:附录107116.〖ZK)〗 [8] 南京中医药大学.中药大辞典[M].上海:上海科学技术出版社,2009:4.〖ZK)〗
点击查看大图
计量
- 文章访问数: 1443
- HTML全文浏览量: 12
- PDF下载量: 1055
- 被引次数: 0